MEDICAL MONITORS

MDM fails to convince the market that it is still a vaible company. Lots of very promising reports but cash is gone.
PBS Challenge:Medical Technology Solutions

Document date: Tue 30 Apr 2002 Published: Wed 01 May 2002 13:30:55
Document No: 215441 Document part: A
Market Flag: N
Classification: Progress Report - Other
MEDICAL MONITORS LIMITED 2002-04-30 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
MEDIA INFORMATION

As the Federal Government searches for ways to rein in the costs of
the Pharmaceutical Benefits Scheme (PBS), the UK's National Health
Service (NHS) has selected a unique Australian blood pressure
monitoring system to help it secure better use of medicines and
improve health cost outcomes in hypertension.

The BPfone (R), a product of local medical technology company Medical
Monitors Limited, has been chosen to be used in a pilot for the NHS
Collaborative National Medicines Management Services Program. It is
one of the most ambitious programs undertaken by the NHS with the UK
Government planning to invest at least GBP 30m over the next three
years.

"We are very proud and encouraged to have the BPfone chosen as the
model for the hypertension component of the NHS' pilot program. If
proven successful, the pilot will become the basis for the management
and monitoring of blood pressure throughout the 302 PCTs in the UK,"
explained Dr Allan Shell, Managing Director, Medical Monitors
Limited.*

The BPfone is a portable, hand-held recording device that enables a
person to take their blood pressure, store a number of recordings and
then transmit the recorded data at any time, via a standard telephone
to a monitoring centre. The data is analysed, reported on and sent
back in an easy to read format to the doctor for consultation.

"The UK health system like the Australian health system, is looking
for more effective ways of using medicines whilst improving patient
care and meeting budgetary requirements," said Dr Allan Shell.

Hypertension affects more than 12 million people in the UK and
cardiovascular disease costs the government approximately GBP 10
billion, making it one of the priority areas in the NHS restructure.

"In the UK pilot program, the BPfone will be used to improve the
diagnosis and management Of hypertension. The BPfone is an important
management and evaluation tool as it enables GPs to make a more
accurate and informed decision regarding their patients'
anti-hypertensive therapy," said Dr Shell.

Importantly, the BPfone also helps to overcome the problem of
'white-coat hypertension' which has been shown to be responsible for
almost 25 per cent of patients diagnosed with hypertension, a recent
Australian study has found. (1)

In Australia, the anti-hypertensive market is worth an estimated $300
million annually and is speculated to be receiving increased
attention in the May budget. Hypertension affects more than three
million Australians, a figure destined to increase substantially with
Australia's ageing population. Medical Monitors Limited is an
Australian health service and medical technology company that enables
people to simply and effectively monitor specific cardiovascular
conditions through unique technology. Medical Monitors is the sole
provider of an Australia-wide monitoring service that is attracting
strong interest from major healthcare players internationally.

You can visit the Medical Monitors website on www.medmon.com.au

For further information please contact Maria Padua on 02 9554 8057 or
0419 200 935.


* The NHS pilot is being managed by Medical Monitors' joint venture
partner in the UK, the Primary Care Group Ltd.



Net financing cash flows - 3,125

Net increase (decrease) in cash held (947) 145

1.21 Cash at beginning of quarter/
year to date 1,022 (70)

1.22 Exchange rate adjustments to item 1.20 - -

1.23 Cash at end of quarter 75 75